Physician profile
Ashley Wright
NPI 1083155006
$7,485.70
in general payments reported to CMS, 2019-2025
59 companies · $1,874 in 2025
The $1,874 reported for 2025 was more than what 94% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $197 · 2022: $1,701 · 2023: $1,788 · 2024: $1,926 · 2025: $1,874.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,468 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,468.34 |
| Education | $119.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $803.84 | 2022-2025 | Calquence, Imfinzi, Lynparza |
| Seagen INC. | $746.01 | 2021-2023 | Tukysa, Padcev, Adcetris |
| Pfizer INC. | $426.10 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $407.43 | 2022-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Exelixis INC. | $394.18 | 2022-2025 | Cabometyx |
| Novartis Pharmaceuticals Corporation | $379.93 | 2022-2025 | |
| Janssen Biotech, INC. | $359.87 | 2022-2025 | Erleada, Rybrevant, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $293.68 | 2022-2025 | Opdivo, Reblozyl, Opdualag |
| Abbvie INC. | $269.59 | 2023-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $254.60 | 2022-2023 | Imbruvica, Epkinly |
| Daiichi Sankyo INC. | $235.88 | 2023-2025 | Enhertu |
| Incyte Corporation | $218.47 | 2022-2025 | Jakafi |
| Janssen Scientific Affairs, LLC | $203.98 | 2023-2025 | Rybrevant, Tecvayli, Darzalex |
| Glaxosmithkline, LLC. | $160.87 | 2022-2025 | Jemperli, Ojjaara, Zejula |
| Celgene Corporation | $155.76 | 2022-2025 | Reblozyl |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.